WEKO3
AND
アイテム
{"_buckets": {"deposit": "6ae17830-7eba-4eb0-9fa4-e1d71a656cb4"}, "_deposit": {"id": "16300", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "16300"}, "status": "published"}, "_oai": {"id": "oai:niigata-u.repo.nii.ac.jp:00016300"}, "item_7_alternative_title_1": {"attribute_name": "\u305d\u306e\u4ed6\u306e\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_alternative_title": "Cytokine Therapy of Renal Cell Cancer"}]}, "item_7_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "1998-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "692", "bibliographicPageStart": "690", "bibliographicVolumeNumber": "112", "bibliographic_titles": [{"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c"}, {"bibliographic_title": "\u65b0\u6f5f\u533b\u5b66\u4f1a\u96d1\u8a8c", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "Metastatic renal cell cancer (RCC) is usually treated with immunotherapy using cytokines because it is a mostly chemoresistant malignancy. These therapies are generally based on interleukin-2 (IL-2) or interferon. However, their response rates were less than 20% and various side effects appeared. In order to improve response rate or reduce side effects, we have tried LAK (lymphokine-activated killer cells) therapy and low dose interferon \u03b3 therapy. LAK cells are peripheral blood lymphocytes activated in vitro by exposure to IL-2. LAK therapy was done 10 course for 9 patients in our hospital and the overall respones rate was 60%. On the other hand, low dose interferon \u03b3 therapy was done for 10 patients and the side effects were relatively small with the response rate of 10%. These results indicate that immunotherapy using cytokines are useful for metastatic renal cancer and its strategy, including dosage, combination therapy, is still to be investigated.", "subitem_description_type": "Abstract"}]}, "item_7_full_name_3": {"attribute_name": "\u8457\u8005\u5225\u540d", "attribute_value_mlt": [{"nameIdentifiers": [{"nameIdentifier": "103950", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Saito, Toshihiro"}]}, {"nameIdentifiers": [{"nameIdentifier": "103951", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Katagiri, Akiyoshi"}]}, {"nameIdentifiers": [{"nameIdentifier": "103952", "nameIdentifierScheme": "WEKO"}], "names": [{"name": "Tomiya, Yoshihiko"}]}]}, "item_7_publisher_7": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "\u65b0\u6f5f\u533b\u5b66\u4f1a"}]}, "item_7_select_19": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_7_source_id_11": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AN00182415", "subitem_source_identifier_type": "NCID"}]}, "item_7_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00290440", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "\u658e\u85e4, \u4fca\u5f18"}], "nameIdentifiers": [{"nameIdentifier": "103947", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u7247\u6850, \u660e\u5584"}], "nameIdentifiers": [{"nameIdentifier": "103948", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "\u51a8\u7530, \u5584\u5f66"}], "nameIdentifiers": [{"nameIdentifier": "103949", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-08-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "112(11)_690-692.pdf", "filesize": [{"value": "523.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 523400.0, "url": {"label": "112(11)_690-692.pdf", "url": "https://niigata-u.repo.nii.ac.jp/record/16300/files/112(11)_690-692.pdf"}, "version_id": "c263e814-f83f-45c3-8360-19abc4b8397f"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "renal cell cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "cytokine therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "interferon", "subitem_subject_scheme": "Other"}, {"subitem_subject": "interleukin-2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u814e\u7d30\u80de\u764c", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u6cbb\u7642", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u30a4\u30f3\u30bf\u30fc\u30d5\u30a7\u30ed\u30f3", "subitem_subject_scheme": "Other"}, {"subitem_subject": "\u30a4\u30f3\u30bf\u30fc\u30ed\u30a4\u30ad\u30f32", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "6)\u814e\u7d30\u80de\u764c\u306b\u5bfe\u3059\u308b\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u6cbb\u7642\uff08\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u306e\u57fa\u790e\u3068\u81e8\u5e8a\u5fdc\u7528, \u7b2c537\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a\uff09", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "6)\u814e\u7d30\u80de\u764c\u306b\u5bfe\u3059\u308b\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u6cbb\u7642\uff08\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u306e\u57fa\u790e\u3068\u81e8\u5e8a\u5fdc\u7528, \u7b2c537\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a\uff09"}, {"subitem_title": "6)\u814e\u7d30\u80de\u764c\u306b\u5bfe\u3059\u308b\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u6cbb\u7642\uff08\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u306e\u57fa\u790e\u3068\u81e8\u5e8a\u5fdc\u7528, \u7b2c537\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a\uff09", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "1", "path": ["453/456", "471/537/538/1102"], "permalink_uri": "http://hdl.handle.net/10191/46337", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_value": "2017-02-10"}, "publish_date": "2017-02-10", "publish_status": "0", "recid": "16300", "relation": {}, "relation_version_is_last": true, "title": ["6)\u814e\u7d30\u80de\u764c\u306b\u5bfe\u3059\u308b\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u6cbb\u7642\uff08\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0 \u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u306e\u57fa\u790e\u3068\u81e8\u5e8a\u5fdc\u7528, \u7b2c537\u56de\u65b0\u6f5f\u533b\u5b66\u4f1a\uff09"], "weko_shared_id": null}
6)腎細胞癌に対するサイトカイン治療(シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会)
http://hdl.handle.net/10191/46337
bcb09ea9-1eb8-46e8-809b-521a0facca58
名前 / ファイル | ライセンス | アクション | |
---|---|---|---|
![]() |
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-02-10 | |||||
タイトル | ||||||
タイトル | 6)腎細胞癌に対するサイトカイン治療(シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会) | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | 6)腎細胞癌に対するサイトカイン治療(シンポジウム サイトカインの基礎と臨床応用, 第537回新潟医学会) | |||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | renal cell cancer | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | cytokine therapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | interferon | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | interleukin-2 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 腎細胞癌 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | サイトカイン治療 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | インターフェロン | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | インターロイキン2 | |||||
資源タイプ | ||||||
資源 | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | departmental bulletin paper | |||||
その他のタイトル | ||||||
その他のタイトル | Cytokine Therapy of Renal Cell Cancer | |||||
著者 |
斎藤, 俊弘
× 斎藤, 俊弘× 片桐, 明善× 冨田, 善彦 |
|||||
著者別名 | ||||||
識別子 | ||||||
識別子 | 103950 | |||||
識別子Scheme | WEKO | |||||
姓名 | ||||||
姓名 | Saito, Toshihiro | |||||
著者別名 | ||||||
識別子 | ||||||
識別子 | 103951 | |||||
識別子Scheme | WEKO | |||||
姓名 | ||||||
姓名 | Katagiri, Akiyoshi | |||||
著者別名 | ||||||
識別子 | ||||||
識別子 | 103952 | |||||
識別子Scheme | WEKO | |||||
姓名 | ||||||
姓名 | Tomiya, Yoshihiko | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Metastatic renal cell cancer (RCC) is usually treated with immunotherapy using cytokines because it is a mostly chemoresistant malignancy. These therapies are generally based on interleukin-2 (IL-2) or interferon. However, their response rates were less than 20% and various side effects appeared. In order to improve response rate or reduce side effects, we have tried LAK (lymphokine-activated killer cells) therapy and low dose interferon γ therapy. LAK cells are peripheral blood lymphocytes activated in vitro by exposure to IL-2. LAK therapy was done 10 course for 9 patients in our hospital and the overall respones rate was 60%. On the other hand, low dose interferon γ therapy was done for 10 patients and the side effects were relatively small with the response rate of 10%. These results indicate that immunotherapy using cytokines are useful for metastatic renal cancer and its strategy, including dosage, combination therapy, is still to be investigated. | |||||
書誌情報 |
新潟医学会雑誌 en : 新潟医学会雑誌 巻 112, 号 11, p. 690-692, 発行日 1998-11 |
|||||
出版者 | ||||||
出版者 | 新潟医学会 | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00290440 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AN00182415 | |||||
著者版フラグ | ||||||
値 | publisher |